Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Gynecologic 1

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vaping 1Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Stomach Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Neoplasms by Histologic Type 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × BID protein, human × Clear all
NCT07090369 2025-07-29

LumOnate

Peter MacCallum Cancer Centre, Australia

Phase 1 Not yet recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT04421222 2025-02-28

EPI-7386

ESSA Pharmaceuticals

Phase 1 Terminated
71 enrolled
Genitourinary

Prostatic Neoplasms

NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

NCT00405210 2011-05-23

Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1 Completed
38 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡